8 results about "Serine hydroxymethyltransferase" patented technology

The invention discloses a serine hydroxymethyltransferase mutant and an application thereof in production of L-serin.The serine hydroxymethyltransferase mutant with the specific enzyme activity remarkably improved is obtained by conducting saturated mutation on serine hydroxymethyltransferase from escherichia coli and conducting screening, and the serine hydroxymethyltransferase mutant is applied to synthesis of L-serine. The serine hydroxymethyltransferase disclosed by the invention can be used for effectively improving the efficiency of catalyzing glycine and formaldehyde to synthesize L-serine by using the serine hydroxymethyltransferase, reducing the enzyme dosage, remarkably reducing the production cost and reducing the separation difficulty of downstream products.

The present disclosure provides methods for treating cancer using ferroptosis inducers in combination with one-carbon metabolism inhibitors. The combination of ferroptosis inducers and one-carbon metabolism inhibitors induce greater ferroptosis than treatment with either alone. In certain embodiments, the one-carbon metabolism inhibitors are serine hydroxymethyltransferase (SHMT) inhibitors and / or methylenetetrahydrofolate dehydrogenase (MTHFD) inhibitors. By way of example, the ferroptosis inducers are GPX4 inhibitors.

The present invention relates to a genetically engineered microorganism expressing (i) formate tetrahydrofolate (THF) ligase, methenyi-THF cyclohydrolase and methylene-THF dehydrogenase, (ii) the enzymes of the glycine cleavage system (GCS), (iii) serine deaminase and serine hydroxymethyltransferase (SHMT), (iv) an enzyme increasing the availability of NADPH, and (v) optionally formate dehydrogenase (FDH), and wherein the genetically engineered microorganism has been genetically engineered to express at least one of the enzymes of (i) to (v), wheren said enzyme is not expressed by the corresponding microorganism that has been used to prepare the genetically engineered microorganism, and wherein the enzymes of (i) to (v) are genomically expressed.

The invention belongs to the technical field of biology, and particularly relates to a serine hydroxymethyltransferase mutant and application thereof. Compared with a wild type serine hydroxymethyltransferase mutant, the serine hydroxymethyltransferase mutant has the advantage that the enzyme activity is obviously improved, so that the mutant or a cell containing the mutant can improve the yield and / or the yield of L-serine.

The invention discloses a bacillus licheniformis recombinant strain with high yield of L-cysteine, and belongs to the technical field of synthetic biology and microbial metabolism engineering. The cysteine synthesis flux is enhanced through multiple knockout and combined overexpression. An efficient engineering strain is constructed by knocking out a serine hydroxymethyltransferase coding gene glyA and an L-serine ammonolysis enzyme coding gene sdaAA of a serine catabolism key pathway, knocking out a cysteine catabolism gene metC and combining gene overexpression to introduce a feedback inhibition removal mutant cysEf and a transporter eamA, and the efficient engineering strain is used for preparing a recombinant strain. Finally, the yield of the L-cysteine reaches 1.075 g / L in shake flask fermentation (the conversion rate is 18.69%), and the application potential of the bacillus licheniformis in sulfur metabolism engineering is highlighted.

The invention relates to an application of glyA-coded serine hydroxymethyltransferase in preparation of L-serine, in particular to an application of glyA-coded serine hydroxymethyltransferase in preparation of L-serine. Specifically, the invention provides a genetically engineered bacterium, and the sequence of a ribosome binding site of a glyA gene in the bacterium is shown as any one of SEQ ID NO: 53-58. The invention also provides a construction method of the genetically engineered bacterium for producing the L-serine or the L-serine derivative, and the ribosome binding site of the glyA gene of the bacterium is replaced by the ribosome binding site as shown in SEQ ID NO: 57 or 58.

The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Serine Hydroxymethyltransferase 2 (SHMT2). Further provided are methods for preparing such cells and methods for using such cells for the production of recombinant proteins.

Provided are a hydroxymethyltransferase and a use of a cofactor or metabolic substrate thereof in preparation of drugs for treating neurodegenerative diseases. Specifically, a hydroxymethyl transfer reaction is performed on glycine residues in protein aggregates such as Poly-GA, Poly-GR, and TDP-43 by means of serine hydroxymethyltransferase 1 (SHMT1) and serine hydroxymethyltransferase 2 (SHMT2), so that the aggregates are degraded, thereby reducing pathological aggregation, and thus ameliorating the pathological condition of patients with neurodegenerative diseases such as ALS and FTD and delaying disease progression. A cofactor and a metabolic substrate of the hydroxymethyltransferase can promote the activity of the hydroxymethyltransferase, thereby enhancing the hydroxymethyl transfer effect on the aggregates such as Poly-GA, Poly-GR and TDP-43, and thus can also be used for treatment of the neurodegenerative diseases such as ALS and FTD.